Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ZOSANO PHARMA CORPORATION

(ZSAN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
0.6289(c) 0.6292(c) 0.6354(c) 0.6416(c) 0.6342(c) Last
465 413 695 674 590 523 497 235 511 786 Volume
+0.19% +0.05% +0.99% +0.98% -1.15% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1,80 M - -
Net income 2021 -28,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,38x
Yield 2021 -
Sales 2022 15,3 M - -
Net income 2022 -34,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,35x
Yield 2022 -
Capitalization 73,3 M 73,3 M -
Capi. / Sales 2021 40,8x
Capi. / Sales 2022 4,78x
Nbr of Employees 45
Free-Float 99,6%
More Financials
Company
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The Company is focused on providing systemic administration of therapeutics to patients using its ransdermal microneedle system (the System). The System is designed to facilitate drug absorption into the bloodstream, which can result in an improved pharmacokinetic profile compared to original dosage forms. The CompanyÔÇÖs lead product candidate... 
More about the company
Ratings of Zosano Pharma Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ZOSANO PHARMA CORPORATION
10/06ZOSANO PHARMA CORP : Change in Directors or Principal Officers, Other Events (form 8-K)
AQ
10/06Zosano Pharma Corporation Announces Executive Changes
CI
10/04ZOSANO PHARMA : Granted Type C Meeting with FDA Regarding NDA Resubmission for M207 Follow..
PU
10/04ZOSANO PHARMA CORP : Entry into a Material Definitive Agreement, Other Events, Financial S..
AQ
10/04ZOSANO PHARMA : Granted Type C Meeting with FDA Regarding NDA Resubmission for M207 Follow..
AQ
10/04Zosano Pharma Corporation Granted Type C Meeting with FDA Regarding NDA Resubmission fo..
CI
09/03ZOSANO PHARMA : to Present at the H.C. Wainwright Virtual Global Investment Conference
AQ
09/02Zosano Pharma to Present at the H.C. Wainwright Virtual Global Investment Conference
GL
08/10ZOSANO PHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
08/10ZOSANO PHARMA : Reports Second Quarter 2021 Financial Results
AQ
08/10ZOSANO PHARMA : Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
08/10ZOSANO PHARMA CORP : Results of Operations and Financial Condition, Financial Statements a..
AQ
08/10Zosano Pharma Corporation Reports Earnings Results for the Second Quarter Ended June 30..
CI
07/20ZOSANO PHARMA : Announces Issuance of U.S. Patent for Method of Rapidly Achieving Therapeu..
AQ
07/20Zosano Pharma Announces Issuance of U.S. Patent for Method of Rapidly Achieving Therape..
CI
More news
News in other languages on ZOSANO PHARMA CORPORATION

- No features available -

More news
Analyst Recommendations on ZOSANO PHARMA CORPORATION
More recommendations
Chart ZOSANO PHARMA CORPORATION
Duration : Period :
Zosano Pharma Corporation Technical Analysis Chart | ZSAN | US98979H2022 | MarketScreener
Technical analysis trends ZOSANO PHARMA CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,63 $
Average target price 2,00 $
Spread / Average Target 215%
EPS Revisions
Managers and Directors
Steven Lo President, Chief Executive Officer & Director
Christine Matthews Chief Financial Officer
Donald J. Kellerman VP-Clinical Development & Medical Affairs
Hayley Lewis Senior Vice President-Operations
Kleanthis G. Xanthopoulos Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ZOSANO PHARMA CORPORATION20.32%73
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414